- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 231/18 - Un atome d'oxygène ou de soufre
Détention brevets de la classe C07D 231/18
Brevets de cette classe: 301
Historique des publications depuis 10 ans
|
27
|
18
|
45
|
31
|
23
|
12
|
13
|
13
|
18
|
9
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Inflazome Limited | 84 |
23 |
| Novartis AG | 10173 |
8 |
| Nippon Soda Co., Ltd. | 885 |
8 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 178 |
8 |
| The University of Queensland | 653 |
8 |
| Bristol-myers Squibb Company | 4757 |
7 |
| Arena Pharmaceuticals, Inc. | 344 |
7 |
| Theravance Biopharma R&D IP, LLC | 360 |
7 |
| Northwestern University | 3557 |
6 |
| Nissan Chemical Corporation | 2248 |
6 |
| VALO Health, Inc. | 193 |
6 |
| Eonhf, Inc. | 45 |
6 |
| BASF SE | 21306 |
5 |
| Bayer Pharma AG | 1009 |
5 |
| The Johns Hopkins University | 5913 |
5 |
| Orsobio, Inc. | 18 |
5 |
| Neuroinnovatech ApS | 11 |
5 |
| Abbott Laboratories | 2241 |
4 |
| Bayer AG | 3522 |
4 |
| Takeda Pharmaceutical Company Limited | 2700 |
4 |
| Autres propriétaires | 164 |